Schizophrenia
Conditions
Interventions
Control group:In the first month, maintenance treatment with atypical antipsychotics plus 10ml of Sweet Dream oral liquid twice daily
in the second month, maintenance treatment with atypical antipsychotics
Experimental Group One:In the first month, atypical antipsychotics were maintained along with 20ml of Tianmeng oral liquid twice daily
in the second month, atypical antipsychotics were maintained.
Experimental Group 2:In the first month, maintenance treatment with atypical antipsychotic drugs plus 20ml of Tianmeng oral liquid orally twice a day
in the second month, maintenance treatment with atypical antipsychotic drugs plus 10ml of Tianmeng oral liquid orally twice a day
Sponsors
Qujing Third People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Patients aged 18-60 who meet the ICD-10 criteria for schizophrenia; 2) PANSS total score =60; 3) Receiving atypical antipsychotic maintenance treatment at therapeutic doses for =12 weeks; and have not used drugs affecting the endocrine system, such as prednisone; 4) Subjects must have a certain level of comprehension, be able to communicate effectively with researchers, and complete study-related assessments; 5) Patient's family members must sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Does not meet the inclusion criteria; (2) Those with a family history of obesity; (3) Renal failure, thyroid dysfunction, ovarian lesions, pituitary tumours; (4) Those with a history of psychoactive drug dependence; (5) Positive urine drug screen, history of alcohol or drug abuse or dependence within the past year; (6) Patients who have used Sweet Dream oral solution without effect in the two months prior to assessment; (7) Patients with mental disorders caused by organic somatic diseases; (8) Uncooperative, unable to communicate, or deemed unsuitable for participation by the researcher; (9) Abnormal liver function indicators (1.5 times higher than the normal value)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum prolactin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Oxytocin;Brain-derived neurotrophic factor;Blood lipids;Liver function;Cognitive Function Scale; | — |
Countries
China
Contacts
Public ContactGao Fei
Qujing Third People's Hospital
Outcome results
None listed